CoChat

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

Open access
Bogaerts, Jan, Sydes, Matthew R., Keat, Nicola, McConnell, Andrea, Benson, Al, Ho, Alan, Roth, Arnaud, Fortpied, Catherine, Eng, Cathy, Peckitt, Clare, Coens, Corneel, Pettaway, Curtis, Arnold, Dirk, Hall, Emma, Marshall, Ernie, Sclafani, Francesco, Hatcher, Helen, Earl, Helena, Ray-Coquard, Isabelle, Paul, James, Blay, Jean-Yves, Whelan, Jeremy, Panageas, Kathy, Wheatley, Keith, Harrington, Kevin, Licitra, Lisa, Billingham, Lucinda, Hensley, Martee, McCabe, Martin, Patel, Poulam M., Carvajal, Richard, Wilson, Richard, Glynne-Jones, Rob, McWilliams, Rob, Leyvraz, Serge, Rao, Sheela, Nicholson, Steve, Filiaci, Virginia, Negrouk, Anastassia, Lacombe, Denis, Dupont, Elisabeth, Pauporté, Iris, Welch, John J., Law, Kate, Trimble, Ted, Seymour, Matthew · 2015 · European Journal of Cancer
Cited by 129

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research. SETTINGS: The International Rare Cancers Initiative (IRCI) is a partnership which aims to stimulate and facilitate the development of international clinical trials for patients with rare cancers. It is focused on interventional--usually randomized--clinical trials with the clear goal of improving outcomes for patients. The key challenges are organisational and methodological. A multi-disciplinary workshop to review the methods used in ICRI portfolio trials was held in Amsterdam in September 2013. Other as-yet unrealised methods were also discussed. RESULTS: The IRCI trials are each presented to exemplify possible approaches to designing credible trials in rare cancers. Researchers may consider these for use in future trials and understand the choices made for each design. INTERPRETATION: Trials can be designed using a wide array of possibilities. There is no 'one size fits all' solution. In order to make progress in the rare diseases, decisions to change practice will have to be based on less direct evidence from clinical trials than in more common diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2014.10.027

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 129

Metadata

Authors
Bogaerts, J., Sydes, M. R., Keat, N., McConnell, A., Benson, A., Ho, A., Roth, A., Fortpied, C., Eng, C., Peckitt, C., Coens, C., Pettaway, C., Arnold, D., Hall, E., Marshall, E., Sclafani, F., Hatcher, H., Earl, H., Ray-Coquard, I., Paul, J., Blay, J.-Y., Whelan, J., Panageas, K., Wheatley, K., Harrington, K., Licitra, L., Billingham, L., Hensley, M., McCabe, M., Patel, P. M., Carvajal, R., Wilson, R., Glynne-Jones, R., McWilliams, R., Leyvraz, S., Rao, S., Nicholson, S., Filiaci, V., Negrouk, A., Lacombe, D., Dupont, E., Pauporté, I., Welch, J. J., Law, K., Trimble, T., & Seymour, M.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2015-02
Volume
51
Issue
3
Pages
271-281
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2117173606
Cited by
129
References
4
FWCI
12.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. https://app.cochat.ai/papers/10.1016/j.ejca.2014.10.027
The paper
Bogaerts, J., Sydes, M. R., Keat, N., McConnell, A., Benson, A., Ho, A., Roth, A., Fortpied, C., Eng, C., Peckitt, C., Coens, C., Pettaway, C., Arnold, D., Hall, E., Marshall, E., Sclafani, F., Hatcher, H., Earl, H., Ray-Coquard, I., . . . Seymour, M. (2015). Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2014.10.027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.